Cargando…

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer

BACKGROUND: The addition of anti-human epidermal growth factor receptor 2 (HER2)-targeted drugs, such as trastuzumab, lapatinib, and trastuzumab emtansine (T-DM1), to chemotherapy significantly improved prognosis of HER2-positive breast cancer patients. However, it was confused that metastatic patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Qing, Qi, Fan, Bian, Li, Zhang, Shao-Hua, Wang, Tao, Jiang, Ze-Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339924/ https://www.ncbi.nlm.nih.gov/pubmed/28229982 http://dx.doi.org/10.4103/0366-6999.200542

Ejemplares similares

A Modified Extraction Method of Circulating Free DNA for Epidermal Growth Factor Receptor Mutation Analysis
por: Yuan, Haihua, et al.
Publicado: (2012)

Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Zhang, Hui-Qiang, et al.
Publicado: (2021)

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
por: Spindler, Karen Lise Garm, et al.
Publicado: (2015)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
por: Yu, Ruofei, et al.
Publicado: (2021)

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018)

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis
por: Liu, Yafang, et al.
Publicado: (2016)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA
por: Sun, Peng, et al.
Publicado: (2019)

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer
por: Topham, James T., et al.
Publicado: (2023)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Detection of clinically relevant epidermal growth factor receptor pathway mutations in circulating cell-free tumor DNA using next generation sequencing in squamous cell carcinoma lung
por: Govind, Kanakasetty Babu, et al.
Publicado: (2019)

Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer
por: Xu, Junnan, et al.
Publicado: (2019)

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
por: Gyanchandani, Rekha, et al.
Publicado: (2016)

A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol
por: Gonzalez-Rivera, Milagros, et al.
Publicado: (2016)

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment
por: Uchida, Junji, et al.
Publicado: (2016)

Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib
por: Shahriari, Saeedeh, et al.
Publicado: (2022)

Adenocarcinoma of the lung with positive epidermal growth factor receptor mutation in pregnancy
por: Amanda, Gina, et al.
Publicado: (2017)

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
por: Gouda, M.A., et al.
Publicado: (2021)

The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients
por: Knuever, Jana, et al.
Publicado: (2020)

The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor
por: Wang, Qi, et al.
Publicado: (2019)

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
por: Martin, Petra, et al.
Publicado: (2016)

Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples
por: Morgan, Shethah R., et al.
Publicado: (2012)

Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients
por: Muendlein, Axel, et al.
Publicado: (2021)

Ultrasensitive Detection of BRAF Mutations in Circulating Tumor DNA of Patients With Metastatic Thyroid Cancer
por: Gouda, Mohamed A, et al.
Publicado: (2021)

Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
por: Kim, Hye-Ryoun, et al.
Publicado: (2013)

Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics
por: Jiao, Jingjing, et al.
Publicado: (2021)

Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report
por: Yue, Li, et al.
Publicado: (2020)

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016)

Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma
por: Levy, Michelle, et al.
Publicado: (2017)

Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer
por: Mirtavoos-Mahyari, Hanifeh, et al.
Publicado: (2019)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
por: Xu, Xiaojing, et al.
Publicado: (2020)

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer
por: Jia, Ning, et al.
Publicado: (2021)

Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
por: Cheng, Xianliang, et al.
Publicado: (2017)

Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer
por: Li, Ze, et al.
Publicado: (2015)

Analyzing microsatellite instability and gene mutation in circulating cell-free DNA to monitor colorectal cancer progression
por: Fu, Yun, et al.
Publicado: (2021)

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study
por: Li, Xuelu, et al.
Publicado: (2019)

Detection of genomic mutations in blood and urine free circulating tumour DNA in patients with inoperable and metastatic lung adenocarcinoma harbouring an EGFR mutation in tissue: a UK pilot study
por: Brooks, Helen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_156sl0cu281iho7lg3l8vvp0d9